We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Ampronix,  Inc

Download Mobile App





Artificial Intelligence and Machine Learning Could Enhance Scientific Peer Review of COVID-19 Papers

By HospiMedica International staff writers
Posted on 16 Sep 2020
Print article
Illustration
Illustration
Scientists have suggested that that artificial intelligence (AI) and machine learning (MK) have the potential to help researchers, clinicians and policymakers to keep up with the vast amount of COVID-related information that is being released and separate the wheat from the chaff.

As the COVID-19 pandemic has continued to sweep across the world, researchers have published hundreds of papers each week reporting their findings, many of which have not undergone a thorough peer review process to gauge their reliability. In some cases, poorly validated research has massively influenced public policy, as when a French team reported COVID patients were cured by a combination of hydroxychloroquine and azithromycin. The claim was widely publicized, and soon US patients were prescribed these drugs under an emergency use authorization. However, further research involving larger numbers of patients cast serious doubts on these claims.

Tudor Oprea, MD, PhD, professor of Medicine and Pharmaceutical Sciences and chief of the Division of Translational Informatics at the University of New Mexico (Albuquerque, NM, USA), notes that the sense of urgency to develop a vaccine and devise effective treatments for the coronavirus has led many scientists to bypass the traditional peer review process by publishing “preprints” - preliminary versions of their work - online. While that enables rapid dissemination of new findings, bad information may lead scientists and clinicians to waste time and money chasing blind leads.

In a commentary published in Nature Biotechnology, Oprea and his colleagues, many of whom work at AI companies, have suggested that AI and ML can harness massive computing power to check many of the claims that are being made in a research paper. Since the COVID epidemic took hold, Oprea himself has used advanced computational methods to help identify existing drugs with potential antiviral activity, culled from a library of thousands of candidates.

“I think there is tremendous potential there,” said Oprea. “I think we are on the cusp of developing tools that will assist with the peer review process.”

Although the tools are not fully developed, “We’re getting really, really close to enabling automated systems to digest tons of publications and look for discrepancies,” he says. “I am not aware of any such system that is currently in place, but we’re suggesting with adequate funding this can become available.”

Text mining, in which a computer combs through millions of pages of text looking for specified patterns, has already been “tremendously helpful,” added Oprea. “We’re making progress in that.”

“We’re not saying we have a cure for peer review deficiency, but we are saying that that a cure is within reach, and we can improve the way the system is currently implemented,” he says. “As soon as next year we may be able to process a lot of these data and serve as additional resources to support the peer review process.”

Related Links:
University of New Mexico


Print article

Channels

Copyright © 2000-2020 Globetech Media. All rights reserved.